ArticleThe American journal of emergency medicine2021
Myocarditis after BNT162b2 vaccination in a healthy male.
Article in The American journal of emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 7 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases.Biomolecules & biomedicine · 2023Pooled it
- Development of myocarditis and pericarditis after COVID-19 vaccination in children and adolescents: A systematic review.Clinical cardiology · 2023Pooled it
- Myocarditis after COVID-19 mRNA vaccination: A systematic review of case reports and case series.Clinical cardiology · 2022Pooled it
- Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis.Diabetes & metabolic syndrome · 2022Pooled it
- Myocarditis Following COVID-19 Vaccination: A Systematic Review of Case Reports.The Yale journal of biology and medicine · 2022Pooled it
- Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine.Journal of medical virology · 2022Pooled it
- Pooled it
- A review of COVID-19 vaccination and the reported cardiac manifestations.Singapore medical journal · 2023Review
- Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.Vaccine: X · 2023Article
- Review
- Recent advances of nanotechnology in COVID 19: A critical review and future perspective.OpenNano · 2023Review
- Diagnostics of messenger ribonucleic acid (mRNA) severe acute respiratory syndrome-corona virus‑2 (SARS-CoV‑2) vaccination-associated myocarditis-A systematic review.Rechtsmedizin (Berlin, Germany) · 2023Review
- Severe Myocarditis in a Female Following mRNA-1273 Vaccine: A Case Report and Review of the Literature.Cureus · 2022Article
- Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review.Medicines (Basel, Switzerland) · 2022Review
- Clinical Characteristics of Patients with Myocarditis following COVID-19 mRNA Vaccination: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Article
- Myocarditis Following COVID-19 Vaccination: Cardiac Imaging Findings in 118 Studies.Tomography (Ann Arbor, Mich.) · 2022Review
- Review
- Review
- The pathogenesis of potential myocarditis induced by COVID-19 vaccine.The American journal of emergency medicine · 2022Article
- Temporal Association Between the COVID-19 Ad26.COV2.S Vaccine and Acute Myocarditis: A Case Report and Literature Review.Cardiovascular revascularization medicine : including molecular interventions · 2022Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocarditis following mRNA COVID-19 vaccination has recently been reported to health authorities in the United States and other countries. Cases predominately occur in young adult males within four days following the second dose of either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines. Although the number of cases reported have been small in comparison with the large number of people vaccinated, myocarditis may be a rare adverse reaction to the COVID-19 vaccination that is now only becoming apparent due to the widespread use of the vaccine. In this article, we present a case of a 20-year-old male with no prior medical history who presented to the emergency department (ED) with chest pain. He had received the BNT162b2 vaccine two days prior to his presentation to the ED. The patient had an elevated troponin at 89 ng/L which increased on repeat examination. His electrocardiogram showed diffuse concave ST segment elevations and a later MRI confirmed the diagnosis of myocarditis. Based on these findings, the patient was diagnosed with myocarditis. The patient had a previous infection with SARS-CoV-2 approximately two months prior to the onset of his symptoms, but since he had fully recovered before the time of his presentation to the ED, it is unlikely that the infection caused the myocarditis. To our knowledge, this is the first published case of myocarditis following BNT162b3 vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.